Furthermore, it has been noted that pharmacological inhibition of CXCR4 also potentiates the effect of ICIs, including anti-PD-1 and PD-L1, in reversing tumor-induced immunosuppression (Park et al., 2022). Here, CXCR4 is linked to neoplasm.